Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × venetoclax × Thoracic × Clear all

Phase

Phase 1 4 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 81 Lymphoid 43 Myeloid 18 Plasma cell 8 Sarcoma 3 Thoracic 1 CNS 1 Breast 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 103 Carboplatin 100 Pemetrexed 63 Cisplatin 63 Nivolumab 55 Paclitaxel 51 Docetaxel 51 Erlotinib Hydrochloride 37 Radiotherapy 35 Gemcitabine 31 Etoposide 29 osimertinib 27 atezolizumab 25 Cetuximab 24 Bevacizumab 23 Ipilimumab 21 Radiosurgery 18 durvalumab 17 Cyclophosphamide 17 Drug Therapy 15 130-nm albumin-bound paclitaxel 15 Irinotecan 13 Albumin-Bound Paclitaxel 13 avelumab 12 Taxes 12 Injections 12 Gefitinib 11 Radiation 10 fludarabine 8 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04543916 2021-03-03

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Virginia Commonwealth University

Phase 1/2 Withdrawn

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡